SE9802864D0 - Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder - Google Patents

Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Info

Publication number
SE9802864D0
SE9802864D0 SE9802864A SE9802864A SE9802864D0 SE 9802864 D0 SE9802864 D0 SE 9802864D0 SE 9802864 A SE9802864 A SE 9802864A SE 9802864 A SE9802864 A SE 9802864A SE 9802864 D0 SE9802864 D0 SE 9802864D0
Authority
SE
Sweden
Prior art keywords
overactive bladder
tolterodine
treatment
antimuscarinic agent
transdermally administered
Prior art date
Application number
SE9802864A
Other languages
English (en)
Swedish (sv)
Inventor
Lene Orup Jacobsen
Bo Kreilgaard
Ulla Hoeck
Helle Kristensen
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20412370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9802864(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9802864A priority Critical patent/SE9802864D0/xx
Publication of SE9802864D0 publication Critical patent/SE9802864D0/xx
Priority to IL13629499A priority patent/IL136294A/en
Priority to HK01104868.0A priority patent/HK1034664B/xx
Priority to APAP/P/2000/001823A priority patent/AP1529A/en
Priority to IDP20001006A priority patent/ID25824A/id
Priority to DE69939382T priority patent/DE69939382D1/de
Priority to MEP-2001-331A priority patent/ME00850B/me
Priority to IL15641499A priority patent/IL156414A0/xx
Priority to AU58918/99A priority patent/AU745190B2/en
Priority to MYPI99003665A priority patent/MY127946A/en
Priority to CZ20001924A priority patent/CZ302630B6/cs
Priority to GE3951A priority patent/GEP20043354B/en
Priority to UA2000052950A priority patent/UA72882C2/uk
Priority to ES99946521T priority patent/ES2353765T3/es
Priority to PCT/SE1999/001464 priority patent/WO2000012070A1/en
Priority to US09/763,654 priority patent/US6517864B1/en
Priority to AT99946522T priority patent/ATE405254T1/de
Priority to NZ504618A priority patent/NZ504618A/xx
Priority to PCT/SE1999/001463 priority patent/WO2000012069A1/en
Priority to NZ509928A priority patent/NZ509928A/en
Priority to ARP990104280A priority patent/AR029311A1/es
Priority to EP99946522A priority patent/EP1105111B1/en
Priority to SK749-2000A priority patent/SK287111B6/sk
Priority to US09/582,498 priority patent/US6770295B1/en
Priority to CNB99801916XA priority patent/CN1239152C/zh
Priority to OA1200000309A priority patent/OA11636A/en
Priority to TR2000/01998T priority patent/TR200001998T1/xx
Priority to JP2000567189A priority patent/JP2002523446A/ja
Priority to PT99946521T priority patent/PT1039882E/pt
Priority to AU58919/99A priority patent/AU758399B2/en
Priority to EP09173927A priority patent/EP2153825A1/en
Priority to CA2311755A priority patent/CA2311755C/en
Priority to ES99946522T priority patent/ES2310942T3/es
Priority to SI9931050T priority patent/SI1039882T1/sl
Priority to HU0100437A priority patent/HUP0100437A3/hu
Priority to AT99946521T priority patent/ATE487471T1/de
Priority to EP99946521A priority patent/EP1039882B1/en
Priority to CA002341063A priority patent/CA2341063C/en
Priority to DK99946521.4T priority patent/DK1039882T3/da
Priority to DE69942928T priority patent/DE69942928D1/de
Priority to EA200000468A priority patent/EA002720B1/ru
Priority to TW088114752A priority patent/TWI253349B/zh
Priority to ZA200002488A priority patent/ZA200002488B/xx
Priority to BG104476A priority patent/BG65168B1/bg
Priority to NO20002977A priority patent/NO329830B1/no
Priority to IS5537A priority patent/IS2976B/is
Priority to US10/301,719 priority patent/US7008637B2/en
Priority to CY20101101027T priority patent/CY1111088T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9802864A 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder SE9802864D0 (sv)

Priority Applications (48)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
IL13629499A IL136294A (en) 1998-08-27 1999-08-26 Use of toltrodine, 5-hydroxy methyl metabolite or its resmat in the preparation of drugs for the treatment of unstable or overactive bladder
HK01104868.0A HK1034664B (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
APAP/P/2000/001823A AP1529A (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release.
IDP20001006A ID25824A (id) 1998-08-27 1999-08-26 Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali
DE69939382T DE69939382D1 (de) 1998-08-27 1999-08-26 Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase
MEP-2001-331A ME00850B (me) 1998-08-27 1999-08-26 Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži
IL15641499A IL156414A0 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
AU58918/99A AU745190B2 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
MYPI99003665A MY127946A (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
CZ20001924A CZ302630B6 (cs) 1998-08-27 1999-08-26 Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu
GE3951A GEP20043354B (en) 1998-08-27 1999-08-26 Therapeutic Formulation for Administering Tolterodine with Controlled Release
UA2000052950A UA72882C2 (uk) 1998-08-27 1999-08-26 Спосіб лікування нестабільності чи надактивності сечового міхура, фармацевтична композиція з регульованим вивільненням та використання толтеродину
ES99946521T ES2353765T3 (es) 1998-08-27 1999-08-26 Formulación terapeútica para administrar tolterodina con liberación controlada.
PCT/SE1999/001464 WO2000012070A1 (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
US09/763,654 US6517864B1 (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
AT99946522T ATE405254T1 (de) 1998-08-27 1999-08-26 Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase
NZ504618A NZ504618A (en) 1998-08-27 1999-08-26 Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
NZ509928A NZ509928A (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
ARP990104280A AR029311A1 (es) 1998-08-27 1999-08-26 UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS.
EP99946522A EP1105111B1 (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
SK749-2000A SK287111B6 (sk) 1998-08-27 1999-08-26 Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
US09/582,498 US6770295B1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
CNB99801916XA CN1239152C (zh) 1998-08-27 1999-08-26 控释给药托耳替罗地的治疗制剂
OA1200000309A OA11636A (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release.
TR2000/01998T TR200001998T1 (tr) 1998-08-27 1999-08-26 Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu
JP2000567189A JP2002523446A (ja) 1998-08-27 1999-08-26 過活動性膀胱の治療のための抗ムスカリン剤としての経皮投与トルテロジン
PT99946521T PT1039882E (pt) 1998-08-27 1999-08-26 Formulação terapêutica para administrar tolterodina com libertação controlada
AU58919/99A AU758399B2 (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
EP09173927A EP2153825A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
CA2311755A CA2311755C (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
ES99946522T ES2310942T3 (es) 1998-08-27 1999-08-26 Tolterodina administrada por via transdermica como agente anti-muscarinico para el tratamiento de vejiga hiperactiva.
SI9931050T SI1039882T1 (sl) 1998-08-27 1999-08-26 Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem
HU0100437A HUP0100437A3 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
AT99946521T ATE487471T1 (de) 1998-08-27 1999-08-26 Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
EP99946521A EP1039882B1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
CA002341063A CA2341063C (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
DK99946521.4T DK1039882T3 (da) 1998-08-27 1999-08-26 Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse
DE69942928T DE69942928D1 (de) 1998-08-27 1999-08-26 Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
EA200000468A EA002720B1 (ru) 1998-08-27 1999-08-26 Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием
TW088114752A TWI253349B (en) 1998-08-27 1999-08-27 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
ZA200002488A ZA200002488B (en) 1998-08-27 2000-05-19 Therapeutic formulation for administering tolterodine with controlled release.
BG104476A BG65168B1 (bg) 1998-08-27 2000-05-26 Фармацевтична форма на толтеродин с контролирано освобождаване
NO20002977A NO329830B1 (no) 1998-08-27 2000-06-09 Oral farmasoytisk formulering inneholdende tolterodin og med kontrollert frigivelse
IS5537A IS2976B (is) 1998-08-27 2000-06-15 Lyfjablanda til inntöku um munn sem inniheldur tolteródín og hefur stýrða losun
US10/301,719 US7008637B2 (en) 1998-08-27 2002-11-22 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
CY20101101027T CY1111088T1 (el) 1998-08-27 2010-11-17 Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
SE9802864D0 true SE9802864D0 (sv) 1998-08-27

Family

ID=20412370

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Country Status (13)

Country Link
US (2) US6517864B1 (https=)
EP (1) EP1105111B1 (https=)
JP (1) JP2002523446A (https=)
AT (1) ATE405254T1 (https=)
AU (1) AU758399B2 (https=)
CA (1) CA2341063C (https=)
DE (1) DE69939382D1 (https=)
ES (2) ES2353765T3 (https=)
NZ (1) NZ509928A (https=)
SE (1) SE9802864D0 (https=)
TW (1) TWI253349B (https=)
WO (1) WO2000012070A1 (https=)
ZA (1) ZA200002488B (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
JP2005513080A (ja) * 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
JP2006515026A (ja) * 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040191345A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
JP5548329B2 (ja) * 2003-08-04 2014-07-16 杏林製薬株式会社 経皮吸収型製剤
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
WO2006082888A1 (ja) * 2005-02-03 2006-08-10 Kyorin Pharmaceutical Co., Ltd. 経皮吸収型製剤
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
EA023147B1 (ru) * 2006-04-13 2016-04-29 Тева Фармасьютикалс Интернешнл Гмбх Трансдермальный пластырь для лечения мигрени
AU2012261753B2 (en) * 2006-04-13 2015-03-05 Teva Pharmaceuticals International Gmbh Transdermal methods and systems for the delivery of anti-migraine compounds
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US20080193766A1 (en) * 2007-02-13 2008-08-14 Northern Nanotechnologies Control of Transport to and from Nanoparticle Surfaces
JP5583003B2 (ja) 2007-04-02 2014-09-03 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
NZ583369A (en) 2007-08-23 2011-08-26 Theracos Inc Benzylbenzene derivatives and methods of use
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090297591A1 (en) * 2008-05-30 2009-12-03 Orient Pharma Co., Ltd. Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds
US20110223204A1 (en) * 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
US8155737B2 (en) * 2008-06-19 2012-04-10 Nupathe, Inc. Pharmacokinetics of iontophoretic sumatriptan administration
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
AU2009270936B2 (en) 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
CN103910702A (zh) 2008-08-22 2014-07-09 泰拉科斯有限公司 制备sglt2抑制剂的方法
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
CA2764526A1 (en) 2009-06-24 2010-12-29 Christine Kritikou The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
KR20110001103A (ko) 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
CN105796533A (zh) * 2009-08-10 2016-07-27 泰华制药国际有限公司 用离子电渗疗法治疗恶心和偏头痛的方法
US20110087153A1 (en) * 2009-10-13 2011-04-14 Angelov Angel S Transdermal Methods And Systems For The Delivery Of Rizatriptan
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
KR101746204B1 (ko) 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
KR20110094858A (ko) * 2010-02-18 2011-08-24 에스케이케미칼주식회사 피부 자극이 감소한 톨테로딘의 경피 투여용 조성물
US20130053357A1 (en) * 2010-04-28 2013-02-28 Hisamitsu Pharmaceutical Co., Inc. Skin irritation suppressant and transdermal preparation
JP6086326B2 (ja) 2010-05-24 2017-03-01 ユニヴァーシティー オブ ロチェスター 二環式ヘテロアリールキナーゼ阻害剤および使用方法
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012017892A1 (ja) 2010-08-03 2012-02-09 久光製薬株式会社 貼付剤及びその粘着力増強方法
EP2654757A1 (en) 2010-12-22 2013-10-30 Entarco SA The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
EP3502236B1 (en) 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CA2868334C (en) 2011-12-27 2020-03-10 Teikoku Seiyaku Co., Ltd. Tolterodine-containing adhesive patch
CA2868534A1 (en) 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
JP2015520754A (ja) 2012-05-18 2015-07-23 オタゴ イノベーション リミテッド 創傷治癒のための組合せ治療および組成物
US10758494B2 (en) 2012-06-12 2020-09-01 KM Transderm Ltd. Rivastigmine-containing adhesive patch
US9895320B2 (en) 2012-09-28 2018-02-20 KM Transderm Ltd. Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
CN103142465B (zh) * 2013-03-19 2014-10-22 长春健欣生物医药科技开发有限公司 一种托特罗定成膜水凝胶制剂及其制备方法
EP3119394B1 (en) 2014-03-19 2021-05-12 Curza Global LLC Compositions and methods comprising 2-(acylamino)imidazoles
US9987361B1 (en) 2014-12-29 2018-06-05 Noven Pharmaceuticals, Inc. Compositions and method for sustained drug delivery by active transdermal technology
JP2020512981A (ja) 2017-03-31 2020-04-30 カーザ グローバル，リミティド ライアビリティ カンパニー 置換２−アミノイミダゾールを含む組成物と方法
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
EP4185310A4 (en) * 2020-07-23 2024-09-04 Kimberly-Clark Worldwide, Inc. METHOD OF MODULATING THE BLADDER MICROBIOME TO IMPROVE BLADDER HEALTH
WO2022098972A1 (en) 2020-11-08 2022-05-12 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
EP4320160A1 (en) 2021-04-09 2024-02-14 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
ZA933349B (en) * 1992-05-13 1994-06-15 Alza Corp Transdermal administration of oxybutynin
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
PT877600E (pt) * 1996-08-09 2004-02-27 Alcon Mfg Ltd Sistemas conservantes para composicoes farmaceuticas contendo ciclodextrinas
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Also Published As

Publication number Publication date
US20030124179A1 (en) 2003-07-03
US7008637B2 (en) 2006-03-07
CA2341063C (en) 2008-02-12
AU5891999A (en) 2000-03-21
ZA200002488B (en) 2001-05-16
ATE405254T1 (de) 2008-09-15
AU758399B2 (en) 2003-03-20
CA2341063A1 (en) 2000-03-09
US6517864B1 (en) 2003-02-11
JP2002523446A (ja) 2002-07-30
WO2000012070A1 (en) 2000-03-09
EP1105111B1 (en) 2008-08-20
TWI253349B (en) 2006-04-21
DE69939382D1 (de) 2008-10-02
EP1105111A1 (en) 2001-06-13
NZ509928A (en) 2003-08-29
ES2353765T3 (es) 2011-03-04
ES2310942T3 (es) 2009-01-16

Similar Documents

Publication Publication Date Title
SE9802864D0 (sv) Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
ATE323473T1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
IS2803B (is) Fentanýlsamsetning fyrir gjöf í nef
ATE290856T1 (de) Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit
MXPA05004381A (es) Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos.
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
IS2789B (is) Lyfjablöndur sem innihalda mónóamínoxídasa B hemla
BRPI0408153A (pt) formulações para administração transdérmica ou transmucosa de agente ativo, métodos de tratamento de distúrbios hormonais em indivìduo, uso de formulação e de melhorador de permeação e kit para tratamento de indivìduo
CA2316349A1 (en) Compositions and method for protecting skin from uv induced immunosuppression and skin damage
DE60134403D1 (de) Behandlung des akuten koronaren syndroms mit glp-1
DE602005018763D1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
CO4410317A1 (es) Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.
SE9601528D0 (sv) Transdermally administered dextromethorphan as antitissue agent
BR9812236A (pt) Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
HUP0203050A2 (hu) Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények
BRPI0407569A (pt) uso de s-10-hidróxi-10, 11-diidro-carbamazepina para o tratamento de ansiendade e distúrbios bipolares
MXPA04010658A (es) Tratamiento de dolor con ifenprodil.
DE602004021233D1 (de) Herabgesetzte dosis von tolterodin zur behandlung von harnwegserkrankungen
DK1011672T3 (da) Anvendelse af (E)-metanicotin derivater til frembringelse af analgetiske virkninger
JP2003300866A (ja) 歯科用表面麻酔剤